Alaunos Therapeutics (TCRT) falls on cash concerns, Nasdaq delisting risk
Alaunos Therapeutics shares fell 6.9% to $2.44 on Thursday, with the company reporting just $354,000 in cash and failing to meet Nasdaq’s $2.5 million equity minimum. Alaunos has not posted revenue and faces possible delisting. The company is promoting its early-stage obesity drug ALN1003, which has shown results only in mouse studies so far.